Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...
The Phase III trial AV001 aims to evaluate QUTENZA® in post- surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after ...